Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-normal”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Testing effectiveness (Phase 2)Looking for participantsNCT06324357
What this trial is testing

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Who this might be right for
Metastatic Breast CancerMetastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+2 more
Boehringer Ingelheim 768
Testing effectiveness (Phase 2)Ended earlyNCT04460430
What this trial is testing

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 12
Testing effectiveness (Phase 2)UnknownNCT04488107
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Who this might be right for
Breast Neoplasms
Ahon Pharmaceutical Co., Ltd. 78
Testing effectiveness (Phase 2)Study completedNCT00952692
What this trial is testing

Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Michael Morse, MD 12
Testing effectiveness (Phase 2)Study completedNCT00356811
What this trial is testing

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 57
Not applicableUnknownNCT04852081
What this trial is testing

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Who this might be right for
Breast Cancer Stage IV
Blokhin's Russian Cancer Research Center 1,000
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Testing effectiveness (Phase 2)Study completedNCT03988036
What this trial is testing

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 46
Testing effectiveness (Phase 2)Ended earlyNCT00754702
What this trial is testing

Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer

Who this might be right for
Breast Cancer
University Hospital of Crete 16
Large-scale testing (Phase 3)Study completedNCT03084939
What this trial is testing

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 351
Not applicableLooking for participantsNCT06328465
What this trial is testing

FREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

Who this might be right for
Invasive Breast CancerHER2-positive Breast CancerTriple Negative Breast Cancer
European Institute of Oncology 145
Early research (Phase 1)Study completedNCT03032107
What this trial is testing

Pembrolizumab In Combination With Trastuzumab-DM1

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 20
Large-scale testing (Phase 3)Study completedNCT01702571
What this trial is testing

Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Who this might be right for
Breast Cancer
Hoffmann-La Roche 2,185
Not applicableStudy completedNCT02654444
What this trial is testing

Semi-Quantification of Her2/Neu Protein Expression in Formalin Fixed, Paraffin-Embedded Normal and Neoplastic Tissue

Who this might be right for
Breast Cancer
Applied Spectral Imaging Ltd. 3
Testing effectiveness (Phase 2)Study completedNCT00960336
What this trial is testing

Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
ARCAGY/ GINECO GROUP 59
Testing effectiveness (Phase 2)Study completedNCT02061332
What this trial is testing

DC Vaccine for Patients With Ductal Carcinoma In Situ

Who this might be right for
Breast CancerDCIS
Abramson Cancer Center at Penn Medicine 58
Large-scale testing (Phase 3)Active Not RecruitingNCT04055493
What this trial is testing

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Who this might be right for
Breast Cancer Female
Women's Cancer Study Group GmbH 1,684
Not applicableLooking for participantsNCT06106477
What this trial is testing

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Medical College of Wisconsin 20
Testing effectiveness (Phase 2)WithdrawnNCT00022230
What this trial is testing

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Who this might be right for
Breast Cancer
Roger Williams Medical Center
Next Page